États-Unis · Plateformes & données · MarketBeat

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

Publié par MarketBeat · États-Unis il y a 2 h

Coherus Oncology (NASDAQ:CHRS) presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

À lire aussi

Glaukos projects $1B 2027 revenue as it raises 2026 net sales guidance to $775M-$785M

Small-Cap Stocks Just Did Something They Haven't Done Since 2018. Is It Finally Time to Buy?

Why Alphabet’s stock could see its worst drop in years after the latest results

Airline groups urge US CDC to reconsider Ebola declaration requirements

Anvil Research Labs CEO flags buy now, pay later’s hidden debt risk

Oracle Forecasts $30B Cash Flow By FY29, Helping Calm AI Capex Concerns, Pushing ORCL Stock To Its Best Day In Five Months

Coherus Oncology Reports 89% Response Rate in Early ESCC Study

Partager

À lire aussi

Glaukos projects $1B 2027 revenue as it raises 2026 net sales guidance to $775M-$785M

Small-Cap Stocks Just Did Something They Haven't Done Since 2018. Is It Finally Time to Buy?

Why Alphabet’s stock could see its worst drop in years after the latest results

Airline groups urge US CDC to reconsider Ebola declaration requirements

Anvil Research Labs CEO flags buy now, pay later’s hidden debt risk

Oracle Forecasts $30B Cash Flow By FY29, Helping Calm AI Capex Concerns, Pushing ORCL Stock To Its Best Day In Five Months